Infinium Global Research Metabolic Disorders Therapeutics Market | Page 3

Metabolic Disorders Therapeutics Market: Trends and Forecast -2023
the forecast period due to strategic collaborations and acquisition and increased R
& D investment.
Segment Covered
The report on global metabolic disorders therapeutics market covers segments
such as, disease type and product. On the basis of disease type the global metabolic
disorders therapeutics market is categorized into diabetes, obesity,
hypercholesterolemia and lysosomal storage disease. On the basis of product the
global metabolic disorders therapeutics market is categorized into metachromatic
leukodystrophy, globoid leukodystrophy, hepatic encephalopathy and others.
Geographic Coverage
The report provides regional analysis covering geographies such as North America,
Europe, Asia-Pacific, and Rest of the World. In this section the key trends and
market size for each geography is provided over the period of 2015-2023. The
countries covered in the North America region include the U.S., Canada, and
Mexico; while Asia-Pacific includes China, Japan, India, South Korea, Malaysia, and
among others. Moreover, Germany, U.K., France, Spain, and Rest of Europe are
included in the European region. The U.S. drives the growth in the North America
region as it is the largest market in the region. The Asia-pacific region offers a
substantial potential for the market growth owing to rapid growth in markets such
as India and China. The APAC region is projected to experience a growth at a CAGR
of x.x% over the period of 2017-2023.
Major Key Players Mentioned in this Premium Report
The report provides profiles of the companies in the global metabolic disorders
therapeutics market such as, Astazeneca Plc, Novo Nordisk, Sanofi, Merck, Eli Lily,
AbbVie, Actelion Pharmaceuticals, Amicus Therapeutics, Arena Pharmaceuticals
and Biocon.
Report Highlights:
The report provides deep insights on demand forecasts, market trends and micro
and macro indicators. In addition, this report provides insights on the factors that
are driving and restraining the global metabolic disorders therapeutics market.
Moreover, IGR-Growth Matrix analysis given in the report brings an insight on the
investment areas that existing or new market players can consider. The report
3
© Infinium Global Research